The US Food and Drug Administration (FDA) have approved Gilead's HIV prevention injection for twice a year, bringing a powerful and convenient new choice.

The Food and Drug Administration in the United States has approved Gilead's antiviral drug for HIV prevention, to be taken twice a year. The company and some experts have stated that this is a milestone that could help bring the world closer to ending the decades-long HIV epidemic. However, the launch of the injectable drug lenacapavir faces a series of potential threats, including the Trump administration's proposal to cut federal funding for HIV prevention efforts.